Imunon, Inc. Terminates Merger with Eterna Therapeutics
Ticker: IMNN · Form: 8-K · Filed: Apr 11, 2024 · CIK: 749647
| Field | Detail |
|---|---|
| Company | Imunon, INC. (IMNN) |
| Form Type | 8-K |
| Filed Date | Apr 11, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: merger-termination, corporate-action
TL;DR
Imunon just killed its Eterna merger deal, effective April 10th. Big changes ahead.
AI Summary
On April 10, 2024, Imunon, Inc. announced the termination of its previously announced merger agreement with Eterna Therapeutics, Inc. The termination was effective immediately. No specific reasons for the termination were disclosed in the filing.
Why It Matters
This termination could significantly impact the strategic direction and financial outlook for Imunon, Inc., potentially affecting its stock price and future growth prospects.
Risk Assessment
Risk Level: medium — The termination of a merger agreement introduces uncertainty regarding the company's future strategy and potential value realization.
Key Players & Entities
- Imunon, Inc. (company) — Registrant
- Eterna Therapeutics, Inc. (company) — Party to terminated merger agreement
- April 10, 2024 (date) — Effective date of merger termination
FAQ
What was the effective date of the merger termination?
The merger termination was effective immediately as of April 10, 2024.
Which companies were involved in the terminated merger agreement?
Imunon, Inc. and Eterna Therapeutics, Inc. were involved in the terminated merger agreement.
What is Imunon, Inc.'s state of incorporation?
Imunon, Inc. is incorporated in Delaware.
What is Imunon, Inc.'s principal executive office address?
Imunon, Inc.'s principal executive offices are located at 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648-2311.
What was the previous name of Imunon, Inc.?
Imunon, Inc. was formerly known as Celsion Corp, and prior to that, Cheung Laboratories Inc.
Filing Stats: 598 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-04-11 09:00:13
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share IMNN Nasdaq Capital Marke
- $1.00 — pany's common stock had met or exceeded $1.00 per share for 10 consecutive business d
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 14KB
- 0001493152-24-014284.txt ( ) — 247KB
- imnn-20240411.xsd (EX-101.SCH) — 3KB
- imnn-20240411_lab.xml (EX-101.LAB) — 33KB
- imnn-20240411_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On April 10, 2024, Imunon, Inc. (the "Company") received a written notice from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company's common stock had met or exceeded $1.00 per share for 10 consecutive business days. On April 11, 2024, Imunon, Inc. (the "Company") issued a press release announcing resolution of the Company's outstanding deficiency notice from Nasdaq. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. Such information shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Imunon, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated April 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMUNON INC. Dated: April 11, 2024 By: /s/ Jeffrey W. Church Jeffrey W. Church Executive Vice President and Chief Financial Officer